Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
Oct 29, 2024 | Alternative Reimbursement Strategies, Chronic conditions, Client Report, Cost projections, Cost Savings, Direct-to-Employer Contracting, Drug costs, Fair market reimbursement, Forensic claims review, Health care costs, High-cost claims, MedBen Rx, MedBen WellLiving, Prescription, Rx Costs, Transparency, Trend, Wellness
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Oct 15, 2024 | Benefits preservation, Biosimilars, Cost Savings, Drug costs, High-cost claims, Rx Costs, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Sep 13, 2024 | Cancer, Health care costs, Heart disease, High-cost claims, Mental Health, Rx Costs, Survey
Employers say they expect their health care costs to rise 7.8% next year — the highest estimate in more than 15 years — according to the latest Business Group on Health member survey. Even factoring in cost-reducing plan design changes, respondents project costs to...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Jul 5, 2024 | Biosimilars, Cost Savings, Humira, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...